[{"id":"88f3eaef-14f2-44c3-90f7-c4ebafee84e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT07474064","created_at":"2026-03-28T01:40:03.816Z","updated_at":"2026-03-28T01:40:03.816Z","phase":"Phase 2","brief_title":"Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC","source_id_and_acronym":"NCT07474064","lead_sponsor":"chenxu","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Aidixi (disitamab vedotin) • Cdactin-O (CBM588)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 146","initiation":"Initiation: 03/26/2026","start_date":" 03/26/2026","primary_txt":" Primary completion: 03/31/2031","primary_completion_date":" 03/31/2031","study_txt":" Completion: 03/31/2035","study_completion_date":" 03/31/2035","last_update_posted":"2026-03-17"},{"id":"778d6e97-aaea-4385-b9ac-14c267296d2e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07474324","created_at":"2026-03-28T01:42:37.705Z","updated_at":"2026-03-28T01:42:37.705Z","phase":"Phase 2","brief_title":"Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial","source_id_and_acronym":"NCT07474324","lead_sponsor":"The First Affiliated Hospital with Nanjing Medical University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e oxaliplatin • Aidixi (disitamab vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 03/15/2026","start_date":" 03/15/2026","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2026-03-16"},{"id":"cc900cf1-cbd5-4b72-929f-5a7f0c8da6dd","acronym":"KEYNOTE-797","url":"https://clinicaltrials.gov/study/NCT04042701","created_at":"2021-01-18T19:49:50.989Z","updated_at":"2025-02-25T12:37:23.766Z","phase":"Phase 1","brief_title":"DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04042701 - KEYNOTE-797","lead_sponsor":"Daiichi Sankyo","biomarkers":" EGFR • HER-2 • BRAF • ALK • ROS1","pipe":" | ","alterations":" HER-2 positive • BRAF V600E • EGFR mutation • HR positive • BRAF V600 • HER-2 expression • HER-2 underexpression • ALK mutation • ROS1 fusion","tags":["EGFR • HER-2 • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • BRAF V600E • EGFR mutation • HR positive • BRAF V600 • HER-2 expression • HER-2 underexpression • ALK mutation • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 115","initiation":"Initiation: 02/10/2020","start_date":" 02/10/2020","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2025-02-24"},{"id":"3855e768-5b4b-4eb8-a4d2-0cb742f3d2ef","acronym":"","url":"https://clinicaltrials.gov/study/NCT05902494","created_at":"2023-06-15T18:08:40.867Z","updated_at":"2025-02-25T13:49:52.358Z","phase":"","brief_title":"HER2 and LA/mUC: A Multi-country Chart Review Cohort Study","source_id_and_acronym":"NCT05902494","lead_sponsor":"Seagen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 350","initiation":"Initiation: 06/29/2023","start_date":" 06/29/2023","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2025-02-21"},{"id":"624a9976-a05c-4b20-8113-57cccfb1cb75","acronym":"KEYNOTE-D78","url":"https://clinicaltrials.gov/study/NCT04879329","created_at":"2021-05-10T14:53:12.740Z","updated_at":"2025-02-25T13:53:47.511Z","phase":"Phase 2","brief_title":"A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2","source_id_and_acronym":"NCT04879329 - KEYNOTE-D78","lead_sponsor":"Seagen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Aidixi (disitamab vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 372","initiation":"Initiation: 05/03/2022","start_date":" 05/03/2022","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 05/30/2028","study_completion_date":" 05/30/2028","last_update_posted":"2025-02-20"},{"id":"8d3fc0b2-6af5-4276-b9b3-c9f1505975ad","acronym":"KEYNOTE-D74","url":"https://clinicaltrials.gov/study/NCT05911295","created_at":"2023-06-22T20:09:18.721Z","updated_at":"2025-02-25T13:55:18.081Z","phase":"Phase 3","brief_title":"Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2","source_id_and_acronym":"NCT05911295 - KEYNOTE-D74","lead_sponsor":"Seagen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • Aidixi (disitamab vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 09/22/2023","start_date":" 09/22/2023","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 04/30/2029","study_completion_date":" 04/30/2029","last_update_posted":"2025-02-20"},{"id":"308e274e-e2f7-4972-a5fd-9ed7015b2fc2","acronym":"HERIZON-GEA-01","url":"https://clinicaltrials.gov/study/NCT05152147","created_at":"2021-12-09T18:00:29.644Z","updated_at":"2025-02-25T14:02:38.513Z","phase":"Phase 3","brief_title":"A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers","source_id_and_acronym":"NCT05152147 - HERIZON-GEA-01","lead_sponsor":"Jazz Pharmaceuticals","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • cisplatin • 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin • Ziihera (zanidatamab-hrii)"],"overall_status":"Recruiting","enrollment":" Enrollment 918","initiation":"Initiation: 12/02/2021","start_date":" 12/02/2021","primary_txt":" Primary completion: 05/15/2025","primary_completion_date":" 05/15/2025","study_txt":" Completion: 05/15/2026","study_completion_date":" 05/15/2026","last_update_posted":"2025-02-19"},{"id":"5325032a-dfb5-4381-8e59-f5e1418ec3ae","acronym":"DASH","url":"https://clinicaltrials.gov/study/NCT04704661","created_at":"2021-01-19T20:51:17.334Z","updated_at":"2025-02-25T14:02:10.901Z","phase":"Phase 1","brief_title":"Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial","source_id_and_acronym":"NCT04704661 - DASH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • TP53 • ATM • RAS • CD4","pipe":" | ","alterations":" HER-2 positive • TP53 mutation • HER-2 amplification • HER-2 expression • RAS mutation","tags":["HER-2 • TP53 • ATM • RAS • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • TP53 mutation • HER-2 amplification • HER-2 expression • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki) • ceralasertib (AZD6738)"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 08/09/2021","start_date":" 08/09/2021","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2025-02-19"},{"id":"7137bb56-9c9c-4ff1-bf66-4a2cdf70604f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04620187","created_at":"2021-01-19T20:34:19.621Z","updated_at":"2025-02-25T14:07:59.706Z","phase":"Phase 2","brief_title":"Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas","source_id_and_acronym":"NCT04620187","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Kadcyla (ado-trastuzumab emtansine)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 12/24/2020","start_date":" 12/24/2020","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2025-02-18"},{"id":"cd035e16-a5bd-4549-8b20-ab7f6cac0b37","acronym":"","url":"https://clinicaltrials.gov/study/NCT06830382","created_at":"2025-02-25T14:20:48.717Z","updated_at":"2025-02-25T14:20:48.717Z","phase":"Phase 2","brief_title":"HER2-PET as a Precision Imaging Tool for Treatment With HER2-ADC in HER2-expressing mBC","source_id_and_acronym":"NCT06830382","lead_sponsor":"Renske Altena","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 04/01/2025","start_date":" 04/01/2025","primary_txt":" Primary completion: 04/01/2030","primary_completion_date":" 04/01/2030","study_txt":" Completion: 04/01/2032","study_completion_date":" 04/01/2032","last_update_posted":"2025-02-17"},{"id":"56fa4122-48b0-496d-9b08-3036a6a23a21","acronym":"TACTIC-3","url":"https://clinicaltrials.gov/study/NCT05862324","created_at":"2023-05-17T14:05:21.313Z","updated_at":"2025-02-25T14:42:02.177Z","phase":"Phase 1/2","brief_title":"TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)","source_id_and_acronym":"NCT05862324 - TACTIC-3","lead_sponsor":"Triumvira Immunologics, Inc.","biomarkers":" EGFR • HER-2 • BRAF • ALK • CLDN18 • BRCA","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • HER-2 expression • CLDN18.2 positive • ALK translocation • BRCA mutation","tags":["EGFR • HER-2 • BRAF • ALK • CLDN18 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • HER-2 expression • CLDN18.2 positive • ALK translocation • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • cyclophosphamide • fludarabine IV • TAC101-Claudin18.2"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 113","initiation":"Initiation: 08/23/2023","start_date":" 08/23/2023","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2025-02-14"},{"id":"065ef196-20b8-4fd5-a099-c2330533ea52","acronym":"SELECTIO-UC","url":"https://clinicaltrials.gov/study/NCT06820255","created_at":"2025-02-25T15:31:16.755Z","updated_at":"2025-02-25T15:31:16.755Z","phase":"Phase 4","brief_title":"DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer.","source_id_and_acronym":"NCT06820255 - SELECTIO-UC","lead_sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","biomarkers":" HER-2 • PD-L1 • NECTIN4 • TACSTD2","pipe":" | ","alterations":" PD-L1 expression • HER-2 expression","tags":["HER-2 • PD-L1 • NECTIN4 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • gemcitabine • Bavencio (avelumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 135","initiation":"Initiation: 01/07/2025","start_date":" 01/07/2025","primary_txt":" Primary completion: 01/07/2026","primary_completion_date":" 01/07/2026","study_txt":" Completion: 01/07/2027","study_completion_date":" 01/07/2027","last_update_posted":"2025-02-11"},{"id":"5c580042-12c5-412f-80d4-50f64137c3e0","acronym":"CRANBERRY","url":"https://clinicaltrials.gov/study/NCT06813456","created_at":"2025-02-25T16:35:03.518Z","updated_at":"2025-02-25T16:35:03.518Z","phase":"","brief_title":"Implementation of Solid Digital PCR to Support Gold-standard Methods for Evaluation of HER2 Amplification Status: Focus on HER2-low Subtype","source_id_and_acronym":"NCT06813456 - CRANBERRY","lead_sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 234","initiation":"Initiation: 11/08/2024","start_date":" 11/08/2024","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2025-02-07"},{"id":"683158be-dd0a-42cf-9640-03e574df768d","acronym":"SGNDV-005","url":"https://clinicaltrials.gov/study/NCT06003231","created_at":"2023-08-21T14:09:07.249Z","updated_at":"2025-02-25T16:40:09.136Z","phase":"Phase 2","brief_title":"A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2","source_id_and_acronym":"NCT06003231 - SGNDV-005","lead_sponsor":"Seagen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aidixi (disitamab vedotin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 122","initiation":"Initiation: 11/14/2023","start_date":" 11/14/2023","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 05/31/2028","study_completion_date":" 05/31/2028","last_update_posted":"2025-02-07"},{"id":"9eaff877-3912-4232-9211-c73f401a599e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06741540","created_at":"2025-02-25T16:41:58.840Z","updated_at":"2025-02-25T16:41:58.840Z","phase":"","brief_title":"Effects of TDCS Intervention on Neoadjuvant Chemotherapy in Breast Cancer Patients with Mild to Moderate Depression","source_id_and_acronym":"NCT06741540","lead_sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","biomarkers":" HER-2 • ER • PGR • IL6 • TNFA","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2 • ER • PGR • IL6 • TNFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/01/2025","start_date":" 01/01/2025","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2025-02-07"},{"id":"583d3d4e-954b-4daf-9f41-90e56eda49dd","acronym":"DYNASTY-Breast02","url":"https://clinicaltrials.gov/study/NCT06018337","created_at":"2023-08-30T14:09:02.590Z","updated_at":"2025-02-25T16:40:10.354Z","phase":"Phase 3","brief_title":"A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)","source_id_and_acronym":"NCT06018337 - DYNASTY-Breast02","lead_sponsor":"DualityBio Inc.","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 expression • HER-2 underexpression • PGR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression • HER-2 underexpression • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • albumin-bound paclitaxel • trastuzumab pamirtecan (BNT323)"],"overall_status":"Recruiting","enrollment":" Enrollment 532","initiation":"Initiation: 01/18/2024","start_date":" 01/18/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2025-02-06"},{"id":"47a36b91-3872-4bf3-8c5d-910cdf540cd0","acronym":"TUGETHER","url":"https://clinicaltrials.gov/study/NCT04789096","created_at":"2021-03-09T15:52:25.212Z","updated_at":"2025-02-25T16:45:21.897Z","phase":"Phase 2","brief_title":"Tucatinib Together with Pembrolizumab and Trastuzumab","source_id_and_acronym":"NCT04789096 - TUGETHER","lead_sponsor":"Breast Cancer Trials, Australia and New Zealand","biomarkers":" HER-2 • PD-L1","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive • HER-2 amplification • HER-2 expression • PD-L1 negative","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive • HER-2 amplification • HER-2 expression • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • capecitabine • Tukysa (tucatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 03/07/2023","start_date":" 03/07/2023","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2025-02-05"},{"id":"bbd54b62-457a-494d-90d2-1614ae83c172","acronym":"DESTINY-Breast08","url":"https://clinicaltrials.gov/study/NCT04556773","created_at":"2021-01-18T21:46:53.987Z","updated_at":"2025-02-25T16:45:09.442Z","phase":"Phase 1","brief_title":"A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT04556773 - DESTINY-Breast08","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 expression • HER-2 underexpression • PGR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • HER-2 underexpression • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • paclitaxel • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • fulvestrant • Truqap (capivasertib) • anastrozole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 138","initiation":"Initiation: 12/17/2020","start_date":" 12/17/2020","primary_txt":" Primary completion: 08/16/2023","primary_completion_date":" 08/16/2023","study_txt":" Completion: 12/04/2025","study_completion_date":" 12/04/2025","last_update_posted":"2025-02-05"},{"id":"2c723604-428f-416a-9baf-62d59cb55edd","acronym":"","url":"https://clinicaltrials.gov/study/NCT03821233","created_at":"2021-01-18T18:52:38.184Z","updated_at":"2025-02-25T17:36:12.613Z","phase":"Phase 1","brief_title":"A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers","source_id_and_acronym":"NCT03821233","lead_sponsor":"Zymeworks BC Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zanidatamab zovodotin (ZW49)"],"overall_status":"Completed","enrollment":" Enrollment 112","initiation":"Initiation: 04/15/2019","start_date":" 04/15/2019","primary_txt":" Primary completion: 09/27/2024","primary_completion_date":" 09/27/2024","study_txt":" Completion: 10/08/2024","study_completion_date":" 10/08/2024","last_update_posted":"2025-01-29"},{"id":"f4adf1be-e9f2-4aec-9718-ca80187e66aa","acronym":"","url":"https://clinicaltrials.gov/study/NCT04294628","created_at":"2021-01-18T20:50:17.525Z","updated_at":"2025-02-25T17:36:34.350Z","phase":"Phase 1","brief_title":"Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer","source_id_and_acronym":"NCT04294628","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification • HER-2 expression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 09/01/2020","start_date":" 09/01/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-01-29"},{"id":"0866c7b2-9cbc-406b-9fb1-09d9afbc8b40","acronym":"","url":"https://clinicaltrials.gov/study/NCT04144023","created_at":"2021-01-18T20:13:32.067Z","updated_at":"2025-02-25T14:40:20.906Z","phase":"Phase 1","brief_title":"A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ","source_id_and_acronym":"NCT04144023","lead_sponsor":"Mayo Clinic","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 06/27/2019","start_date":" 06/27/2019","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-01-28"},{"id":"08d1e6e8-fb84-46e5-ab28-7d30c69b7fb4","acronym":"DS8201-A-U105","url":"https://clinicaltrials.gov/study/NCT03523572","created_at":"2024-06-16T01:34:24.698Z","updated_at":"2025-02-25T14:26:56.311Z","phase":"Phase 1","brief_title":"Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer","source_id_and_acronym":"NCT03523572 - DS8201-A-U105","lead_sponsor":"Daiichi Sankyo","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Completed","enrollment":" Enrollment 86","initiation":"Initiation: 08/02/2018","start_date":" 08/02/2018","primary_txt":" Primary completion: 07/22/2021","primary_completion_date":" 07/22/2021","study_txt":" Completion: 09/12/2023","study_completion_date":" 09/12/2023","last_update_posted":"2025-01-27"},{"id":"da0d300b-6122-4216-8cdf-188d19179574","acronym":"QL-GasC-QIBA-1001","url":"https://clinicaltrials.gov/study/NCT06766305","created_at":"2025-02-26T07:07:06.834Z","updated_at":"2025-02-26T07:07:06.834Z","phase":"Phase 1/2","brief_title":"QL1706 Combined With SOX Used in Theperioperative Treatment","source_id_and_acronym":"NCT06766305 - QL-GasC-QIBA-1001","lead_sponsor":"Xiangdong Cheng","biomarkers":" HER-2 • PD-L1","pipe":" | ","alterations":" PD-L1 expression • HER-2 expression","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Qibeian (iparomlimab/tuvonralimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 01/01/2025","start_date":" 01/01/2025","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 06/30/2031","study_completion_date":" 06/30/2031","last_update_posted":"2025-01-09"},{"id":"83f56344-90cd-467e-b21a-af268ac41927","acronym":"neovision","url":"https://clinicaltrials.gov/study/NCT06734182","created_at":"2025-02-25T19:17:44.245Z","updated_at":"2025-02-25T19:17:44.245Z","phase":"Phase 2","brief_title":"Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer","source_id_and_acronym":"NCT06734182 - neovision","lead_sponsor":"Guangdong Provincial People's Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" PD-L1 expression • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Aidixi (disitamab vedotin) • Enweida (envafolimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 06/22/2024","start_date":" 06/22/2024","primary_txt":" Primary completion: 06/22/2027","primary_completion_date":" 06/22/2027","study_txt":" Completion: 06/22/2028","study_completion_date":" 06/22/2028","last_update_posted":"2024-12-16"}]